Sweden: A new randomized trial has found that daily low-dose aspirin significantly lowers the risk of colorectal cancer recurrence in patients whose tumors harbor specific PI3K pathway alterations. Published in the New England Journal of Medicine , the study led by Dr. Anna Martling of Karolinska Institutet demonstrates that aspirin not only reduces recurrence among patients with PIK3CA hotspot mutations but also provides similar benefits for those with other high- or moderate-impact variants in PI3K pathway genes. The double-blind, placebo-controlled trial enrolled patients with stage I–III rectal cancer or stage II–III colon cancer who had somatic alterations in PI3K pathway genes, including PIK3CA, PIK3R1, and PTEN. Eligible participants were randomly assigned in a 1:1 ratio

See Full Page